Precipio, Inc. Common Stock (PRPO) Stock Price
PRPOStock
$21.38+14.61%52W
Market Cap$38.27M
P/E—
PEG Ratio—
Div yield—
Beta1.45
PRPO Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-34.91%
Price vs S&P 500 (4W)-18.89%
VGM Score59.89
PRPO Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q3 2023 | -$1.40 | -$1.04 | +25.71%(+$0.36) | |
| Q2 2023 | -$2.00 | -$1.80 | +10.00%(+$0.20) | |
| Q1 2023 | -$2.60 | -$2.60 | +0.00%(+$0.00) |
PRPO Analyst Recommendations
Mar 2024
Apr 2024
May 2024
Jun 2024
4.14
4.14
4.14
4.14
Industry Peers — Lab Analytical Instruments(25)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
PRPOPrecipio, Inc. Common Stock | C | A | C | 1.4x | 31.6% | 44.1% | -5.7% | $21.38 |
| AAgilent Technologies Inc. | D | C | A | 6.6x | 5.4% | 53.9% | 22.2% | $172.97 |
| WATWaters Corp | F | C | A | 9.4x | 6.0% | 50.9% | 7.1% | $436.95 |
| ILMNIllumina Inc | D | D | A | 8.8x | 6.0% | 66.4% | 19.5% | $262.54 |
| MTDMettler-Toledo International | D | C | A | 7.9x | 5.5% | 60.3% | 26.6% | $1622.29 |
| RVTYRevvity, Inc. | D | D | A | 5.8x | -5.5% | 55.0% | 12.3% | $152.64 |
| AVTRAvantor, Inc. | C | F | A | 1.7x | 0.5% | 31.8% | -4.7% | $16.42 |
| BIO.BBio-Rad Laboratories, Inc. Class B | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $364.15 |
| BIOBio-Rad Laboratories, Inc.Class A | C | D | B | 3.7x | 0.3% | 51.9% | 1.8% | $353.70 |
| TXG10x Genomics, Inc. Class A Common Stock | F | D | A | 14.8x | 16.6% | 69.6% | -14.3% | $69.86 |
| BRKRBruker Corporation | D | D | B | 2.4x | 11.6% | 47.7% | -1.5% | $54.80 |
About Precipio, Inc. Common Stock
Precipio Inc develops blood cancer diagnostics designed to reduce misdiagnoses among office-based oncologists. The company operates CLIA-certified laboratories in Connecticut and Nebraska, offering diagnostic products including HemeScreen and IV-Cell to healthcare providers across the United States. Revenue is primarily generated from third-party payers.